Ibio Inc (IBIO)

$1.89 +0.02 (1.07%)
Market Cap 42.50M
Revenue (ttm) 400,000.00
Net Income (ttm) -18.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,595.00%
Debt to Equity Ratio 0.01
Volume 891,900
Avg Vol 9,052,680
Day's Range N/A - N/A
Shares Out 22.49M
Stochastic %K 30%
Beta 1.13
Analysts Strong Sell
Price Target $4.52

Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies agai...

Industry: Biotechnology
Sector: Healthcare
Phone: 979 446 0027
Website: ibioinc.com
Address:
11750 Sorrento Valley Road, Suite 200, San Diego, United States
DrMash
DrMash Dec. 28 at 4:46 PM
$IBIO https://www.ml.com/articles/daily-market-insights-recent.html
1 · Reply
skitime
skitime Dec. 27 at 6:32 PM
$IBIO Exactly the same bull comments as 2016 and 2020 when it was 4k.... 🤔
1 · Reply
DrMash
DrMash Dec. 27 at 4:56 PM
$IBIO We are not yet there $ 4.77 . Why do you want to close out early?. The best is yet to be experienced.
0 · Reply
DrMash
DrMash Dec. 26 at 5:41 PM
$IBIO Keep them order coming. Loading more and more for the green day.
1 · Reply
dcpanda
dcpanda Dec. 26 at 4:48 PM
$IBIO grabbed a few more at 1.8 lets consolidate and get ready for next leg 🍻
1 · Reply
BuyBigly
BuyBigly Dec. 26 at 4:48 PM
$IBIO LOL. $7 price targets and IND. they say the same shit over and over. Its like Groundhog day every year for years. Wake the hell up. Stop listening to these idiot pumpers. They know zilch.
1 · Reply
RelativistR
RelativistR Dec. 26 at 3:04 PM
$IBIO Price action signals that reliability now matters more than headline momentum. Balance sheet resilience remains an underappreciated swing factor. Evidence of repeatability is likely to change market tone. Durable value creation requires execution to catch up with vision.
0 · Reply
TheSultann
TheSultann Dec. 24 at 11:12 PM
$IBIO We need more Shorts for the MOASSs These are not enough
2 · Reply
vikingpurple
vikingpurple Dec. 24 at 9:57 PM
$IBIO Stock Warrants are frequently used in the purchase of companies. Serving as a strategic tool to sweeten the deal. Given the huge amount of analytical evidence, it appears to be a given.
0 · Reply
Techallure
Techallure Dec. 24 at 5:00 PM
$IBIO That’s not the one I am referring to : : : wait for the $7+ target upcoming and its en route Be Prepared
1 · Reply
Latest News on IBIO
iBio to Participate in the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 4:15 PM EST - 4 weeks ago

iBio to Participate in the 8th Annual Evercore Healthcare Conference

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:01 PM EST - 6 weeks ago

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Oct 30, 2025, 7:00 AM EDT - 2 months ago

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 23, 2025, 7:00 AM EDT - 2 months ago

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

Oct 21, 2025, 7:00 AM EDT - 2 months ago

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Sep 5, 2025, 7:30 AM EDT - 4 months ago

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

iBio Announces Closing of $50 Million Public Offering

Aug 25, 2025, 7:00 AM EDT - 4 months ago

iBio Announces Closing of $50 Million Public Offering

iBio Announces Pricing of $50 Million Public Offering

Aug 19, 2025, 8:01 AM EDT - 4 months ago

iBio Announces Pricing of $50 Million Public Offering

iBio Announces Proposed Public Offering

Aug 18, 2025, 4:01 PM EDT - 4 months ago

iBio Announces Proposed Public Offering

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Jun 24, 2025, 7:00 AM EDT - 6 months ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Jun 23, 2025, 4:15 PM EDT - 6 months ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

Jun 16, 2025, 7:00 AM EDT - 6 months ago

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 5, 2025, 8:00 AM EDT - 8 months ago

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

iBio Reports Fiscal Third Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 8 months ago

iBio Reports Fiscal Third Quarter 2025 Financial Results

iBio Raises $6.2 Million Through Warrant Inducement Transaction

Apr 29, 2025, 1:43 PM EDT - 8 months ago

iBio Raises $6.2 Million Through Warrant Inducement Transaction

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 22, 2025, 8:00 AM EDT - 8 months ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Apr 7, 2025, 7:00 AM EDT - 9 months ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 19, 2025, 4:05 PM EST - 11 months ago

iBio to Begin Trading on the Nasdaq Stock Exchange

iBio Reports Fiscal Second Quarter 2025 Financial Results

Feb 10, 2025, 4:05 PM EST - 11 months ago

iBio Reports Fiscal Second Quarter 2025 Financial Results

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Jan 2, 2025, 7:00 AM EST - 1 year ago

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

iBio Reports Fiscal First Quarter 2025 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

iBio Reports Fiscal First Quarter 2025 Financial Results

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sep 20, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

iBio to Participate in Upcoming Investor Conferences

Sep 3, 2024, 7:00 AM EDT - 1 year ago

iBio to Participate in Upcoming Investor Conferences

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Aug 12, 2024, 4:30 PM EDT - 1 year ago

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

iBio Closes Sale of Manufacturing Facility in Texas

Jun 3, 2024, 7:00 AM EDT - 1 year ago

iBio Closes Sale of Manufacturing Facility in Texas

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 2:43 PM EDT - 1 year ago

iBio stock nearly tripled on Wednesday: here's why

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Mar 27, 2024, 7:00 AM EDT - 1 year ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

iBio Announces $15.0 Million Private Placement

Mar 26, 2024, 7:35 PM EDT - 1 year ago

iBio Announces $15.0 Million Private Placement

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Feb 26, 2024, 7:45 AM EST - 1 year ago

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

iBio Announces Participation in 23rd Annual PepTalk Conference

Jan 16, 2024, 8:15 AM EST - 2 years ago

iBio Announces Participation in 23rd Annual PepTalk Conference

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

Jan 16, 2024, 6:50 AM EST - 2 years ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI VYNE

iBio Amends and Extends Maturity of Credit Agreement

Dec 26, 2023, 7:15 AM EST - 2 years ago

iBio Amends and Extends Maturity of Credit Agreement

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Dec 5, 2023, 8:00 AM EST - 2 years ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

iBio Announces Reverse Stock Split

Nov 27, 2023, 5:20 PM EST - 2 years ago

iBio Announces Reverse Stock Split

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Nov 1, 2023, 8:24 AM EDT - 2 years ago

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

iBio Explains Recent Filing of Registration Statement

Oct 2, 2023, 6:45 AM EDT - 2 years ago

iBio Explains Recent Filing of Registration Statement

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 27, 2023, 4:19 PM EDT - 2 years ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

iBio Announces Amendment to Credit Agreement with Woodforest

Sep 21, 2023, 4:05 PM EDT - 2 years ago

iBio Announces Amendment to Credit Agreement with Woodforest

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Aug 14, 2023, 4:15 PM EDT - 2 years ago

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

Jun 27, 2023, 8:00 AM EDT - 2 years ago

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

iBio Forges Research Collaboration with the National Institutes of Health

Jun 12, 2023, 4:15 PM EDT - 2 years ago

iBio Forges Research Collaboration with the National Institutes of Health

iBio to Participate in the JMP Securities Life Sciences Conference

May 9, 2023, 4:30 PM EDT - 2 years ago

iBio to Participate in the JMP Securities Life Sciences Conference

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

Apr 4, 2023, 4:05 PM EDT - 2 years ago

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

Mar 31, 2023, 8:10 AM EDT - 2 years ago

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

Feb 16, 2023, 4:48 PM EST - 3 years ago

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

iBio Announces Closing of $3.5 Million Underwritten Public Offering

Dec 9, 2022, 4:05 PM EST - 3 years ago

iBio Announces Closing of $3.5 Million Underwritten Public Offering

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

Dec 6, 2022, 11:27 PM EST - 3 years ago

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

iBio Announces Proposed Underwritten Public Offering

Dec 6, 2022, 4:01 PM EST - 3 years ago

iBio Announces Proposed Underwritten Public Offering

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

Dec 5, 2022, 8:00 AM EST - 3 years ago

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

DrMash
DrMash Dec. 28 at 4:46 PM
$IBIO https://www.ml.com/articles/daily-market-insights-recent.html
1 · Reply
skitime
skitime Dec. 27 at 6:32 PM
$IBIO Exactly the same bull comments as 2016 and 2020 when it was 4k.... 🤔
1 · Reply
DrMash
DrMash Dec. 27 at 4:56 PM
$IBIO We are not yet there $ 4.77 . Why do you want to close out early?. The best is yet to be experienced.
0 · Reply
DrMash
DrMash Dec. 26 at 5:41 PM
$IBIO Keep them order coming. Loading more and more for the green day.
1 · Reply
dcpanda
dcpanda Dec. 26 at 4:48 PM
$IBIO grabbed a few more at 1.8 lets consolidate and get ready for next leg 🍻
1 · Reply
BuyBigly
BuyBigly Dec. 26 at 4:48 PM
$IBIO LOL. $7 price targets and IND. they say the same shit over and over. Its like Groundhog day every year for years. Wake the hell up. Stop listening to these idiot pumpers. They know zilch.
1 · Reply
RelativistR
RelativistR Dec. 26 at 3:04 PM
$IBIO Price action signals that reliability now matters more than headline momentum. Balance sheet resilience remains an underappreciated swing factor. Evidence of repeatability is likely to change market tone. Durable value creation requires execution to catch up with vision.
0 · Reply
TheSultann
TheSultann Dec. 24 at 11:12 PM
$IBIO We need more Shorts for the MOASSs These are not enough
2 · Reply
vikingpurple
vikingpurple Dec. 24 at 9:57 PM
$IBIO Stock Warrants are frequently used in the purchase of companies. Serving as a strategic tool to sweeten the deal. Given the huge amount of analytical evidence, it appears to be a given.
0 · Reply
Techallure
Techallure Dec. 24 at 5:00 PM
$IBIO That’s not the one I am referring to : : : wait for the $7+ target upcoming and its en route Be Prepared
1 · Reply
DrMash
DrMash Dec. 24 at 4:53 PM
$IBIO https://www.tipranks.com/news/the-fly/ibio-initiated-with-an-outperform-at-lifesci-capital-thefly?utm_source=webullapp.com&utm_medium=referral
0 · Reply
DrMash
DrMash Dec. 24 at 3:30 PM
$IBIO 5 days chart looking good. The stocks has really stood the test of time.
0 · Reply
TheSultann
TheSultann Dec. 24 at 3:25 PM
$IBIO
0 · Reply
Techallure
Techallure Dec. 24 at 12:35 PM
$IBIO The next upgrade to $7+ will turn some heads a bit more Be Prepared
0 · Reply
DrMash
DrMash Dec. 24 at 9:17 AM
$IBIO Analyst rating upgraded to $ 6.
0 · Reply
DrMash
DrMash Dec. 24 at 8:58 AM
$IBIO In summary, institutions owns almost 47% of the total shares issued by the company. Frazier comes 3rd. The case is bullish. Simple.
2 · Reply
DrMash
DrMash Dec. 24 at 8:55 AM
$IBIO in case you missed my update , EcoR1 and Silverarch owns more than 20% of the Ibio shares . See above post
0 · Reply
jlld
jlld Dec. 23 at 10:07 PM
$IBIO Overview +7 Oppenheimer has raised its price target for iBio, Inc. (IBIO) to $6.00 per share from a previous target of $5.00. The firm also maintains an "Outperform" or "Buy" rating on the stock.
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Dec. 23 at 9:28 PM
$IBIO
0 · Reply
BearLifeWithShorts
BearLifeWithShorts Dec. 23 at 7:05 PM
$IBIO $IBIO upcoming catalysts •January 12 JP Morgan Healthcare Conference •IBIO-610 (Activin E antibody) — lead program with promising preclinical news released. •IBIO-600 (Myostatin antibody) — another cardiometabolic asset with positive news. •More institutions entering. Oppenheimer buy rating $5
1 · Reply
DrMash
DrMash Dec. 23 at 4:59 PM
$IBIO Don't mind the SANTA pullback. Panic seller's being swifted . We ain't leaving till we witness above $ 4.5 . Big announcement imminent. The case is Bullish.
0 · Reply
IBIO_KEVINTL
IBIO_KEVINTL Dec. 23 at 3:02 PM
$IBIO Time to buy up End of year sell offs And holiday travel week. Take advantage of the Cheapies!
0 · Reply